从India供应商批发进口Allexi — FOB条款

Allexi is an anti-allergy pharmaceutical formulation supplied by G M Pharma from Maharashtra, India, indicated for relief from allergic rhinitis, urticaria, and other hypersensitivity conditions. The active pharmaceutical ingredient is cetirizine hydrochloride, typically at a standard strength of 10 mg per tablet, with excipients including microcrystalline cellulose, lactose monohydrate, and magnesium stearate. G M Pharma lists this as a non-drowsy, fast-acting preparation available in tablet and liquid oral dosage forms.

The formulation follows standard pharmaceutical manufacturing under GMP guidelines, with batch consistency monitored through dissolution testing and assay validation. Typical tablet weight is 200-250 mg, with hardness of 4-7 kp and disintegration time under 30 minutes per USP standards. The liquid formulation typically contains cetirizine dihydrochloride 1 mg/ml with standardized pH buffering to maintain stability. Packaging is standard for Indian pharmaceutical exports, typically blister packs of 10 tablets or PET bottles of 60 ml liquid, though exact packaging specifications should be confirmed directly with G M Pharma.

Primary buyers include hospital procurement departments, retail pharmacy chains, and pharmaceutical distributors serving allergy and respiratory therapeutic categories. The product is suitable for both human prescription and over-the-counter markets depending on local regulatory classification. Importing buyers should verify registration status, stability data, and specific certificate of analysis requirements with G M Pharma before placing orders, as the listing does not specify current GMP certification dates, export licences, or validated cold chain parameters.

G M Pharma operates from Karad, Maharashtra, India, with its registered address at Shree Chambers, Shop No 6. The supplier holds a 'harbor' trust tier designation, though this should be independently verified through direct credential review rather than platform-assigned labels. The response rate is recorded at 0.00 percent with zero average response hours, indicating that direct communication channels may be underutilised or that the supplier prefers initial contact through alternative methods. Buyers should expect to follow up proactively to establish working contact.

The listing does not disclose manufacturing site certifications, current GMP audit dates, specific export licences, or regulatory approvals held by G M Pharma. No employee count, annual turnover, or client references are provided. The supplier's product focus appears to be generic pharmaceutical formulations for allergy and respiratory categories. Buyers are advised to request a complete regulatory dossier, including manufacturing site master file, current GMP certificate, product-specific stability data, and country-specific registration support capabilities before committing to supply agreements.